Navigation Links
New technology for a more efficient treatment of Pompe disease and other metabolic disorders
Date:11/19/2012

VIB researchers from UGent and Vrije Universiteit Brussel , together with a team of the firm Oxyrane have developed a new technology that can lead to a more efficient and possibly also cheaper therapy for diseases such as Pompe disease. Oxyrane will now start developing a clinical program for this therapy in Pompe disease.

Nico Callewaert (VIB-UGent): "By combining natural processes and proteins of two microbes and a plant we have improved the technology to produce enzymes that patients with metabolic disorders can't produce themselves. We played with the sugar structures on the enzymes. As a result these enzymes were directed much more efficient to the locations in the cells where they actually have to work. It shows once again what medical biotechnology can accomplish."

Han Remaut (VIB-VUB): "The lacking piece of the jigsaw in this technology was a protein we discovered in a soil bacterium. Thanks to the detailed picture we obtained from the 3D structure of this novel protein, we now understand how it comes to its unique reaction specificity and how we could further improve it".

Wouter Vervecken (Oxyrane): "Data suggest that this platform has the potential to enable production of more efficacious therapies in the years to come. The results are very encouraging the enzyme for the treatment of Pompe disease is absorbed 17 times as efficiently by patient cells in vitro than current treatments".

Lysosomal storage diseases

1 in 5000 newborns has a lysosomal storage disease, but it can also cause symptoms later in life. In all the cells of our body you can find lysosomes. They are responsible for breaking down cell components to be reused by the cell. In lysosomal storage diseases, one or more of the enzymes that accomplish this process are lacking or insufficient. The result is that the non-processed substances accumulate in the lysosomes and eventually poison the cell, leading to organ damage that keeps on worsening if left untreated. One example is Pompe disease, which affects the muscles.

Treatments for these illnesses

Lysosomal storage diseases can be treated with the lacking enzymes, provided they end up in the patient's lysosomes; this is known as Enzyme Replacement Therapy (ERT). This can be accomplished by adding a specific modified sugar to the enzymes, i.e. mannose-6-phosphate, but this is not easy to do. Until now such modified enzymes could only be produced more or less successfully in mammalian cells. The VIB researchers, together with Oxyrane, have developed a novel, more efficient method that uses yeast cells instead.

A new technology for a more efficient production

The result is impressive the enzyme for the treatment of Pompe's disease is absorbed 17 times as efficiently by patient cells in vitro than the current therapeutic drug. In a Pompe disease mouse model the enzyme also worked better than the current therapeutic product. Based on these results Oxyrane will start clinical trials for Pompe disease, this means that it will be tested in humans for the first time.


'/>"/>
Contact: Kris Van der Beken
kris.vanderbeken@vib.be
32-473-783-435
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related medicine news :

1. Mechanical tissue resuscitation technology shows promise
2. New study identifies how information technology is used to solve global health challenges
3. Power generation technology based on piezoelectric nanocomposite materials developed by KAIST
4. Simulation technology allows users to safely practice phacoemulsification cataract surgery
5. The Casey Group's Sales Navigator Wins 2012 Best Mobility App in the New Jersey Technology Council's Mobile Application Competition
6. Swanson Health Products Introduces a New Alkalizing Drink Mix, Swanson® pH Balance Alka-Tone with Alka-Plex™ Technology
7. Miami Children’s Hospital Performs First Nerve Repair Surgery Using Avance® Nerve Graft Technology
8. FDA Approves SonixGPS Needle Guidance Technology for Vascular Access Procedures
9. IVR Technology Group Named Platimum VAR by TSYS
10. 3M™ Gripping Material Technology – Giving Golfers a Competitive Edge
11. Newer technology to control blood sugar works better than conventional methods
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Southern ... and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice Frueh, ... cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU School ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Global Healthcare ... scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare ... activity. The fun run is geared towards children of all ages; it is ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... for healthcare compliance program management, will showcase a range of technology and learning ... Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 at ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)...  Commended for their devotion to personalized service, SMP Pharmacy ... one in the South Florida Business Journal,s 50 Fastest-Growing Companies, ... list, the national specialty pharmacy has found its niche.  To ... soon be honored by SFBJ as the 2017 Power Leader ... to receive his award in October, Bardisa said of the ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
(Date:9/19/2017)... 19, 2017   ZirMed Inc ., a recognized leader ... that it has been ranked #1 by its users for ... Rankings 2017 User Survey. ZirMed was recognized as the top-ranked ... and medical centers over 200 beds and holds one of ... user survey history. ...
Breaking Medicine Technology: